Evidence map›Paper›PMID 41771847›Full record

ArticleCell death & disease2026

Targeting the FNIP2-SERCA2b axis improves metabolic and mitochondrial defects in Ataxia Telangiectasia.

Maria Vinciguerra, Catiana El Kharef, Christopher Bruhn, Lucia Falbo, Chiara Milanese, Matteo Audano, Galina V Beznoussenko, Alexander A Mironov, Domenico Delia, Marco Foiani and 3 more

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maria Vinciguerra *IFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.
Catiana El Kharef *IFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.
Christopher Bruhn *IFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.
Lucia Falbo *IFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID http://orcid.org/0000-0003-2452-8814
Chiara MilaneseIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID http://orcid.org/0000-0001-8696-2603
Matteo AudanoDepartment of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", University of Milan, Milan, Italy.
Galina V BeznoussenkoIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.
Alexander A MironovIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.
Domenico DeliaIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.
Marco FoianiIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.
Pier Giorgio MastroberardinoIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.
Nico MitroDepartment of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", University of Milan, Milan, Italy.ORCID http://orcid.org/0000-0002-5000-3619
Vincenzo CostanzoIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy. Vincenzo.Costanzo@IFOM.EU.ORCID http://orcid.org/0000-0002-2920-9508

Funding

Action for A-T (Action for Ataxia Telangiectasia) N/A
6 · The paper itself

Abstract

Ataxia telangiectasia (AT) is a rare multisystem disorder caused by the loss of functional ATM protein, leading to immunodeficiency, cancer predisposition, neurodegeneration, diabetes, heart failure, and premature aging. Although ATM's role as a sensor of DNA double-strand breaks (DSBs) is well established, the mechanisms underlying the diverse AT phenotypes remain incompletely understood, with evidence suggesting they extend beyond DSB sensing. Here, we uncover widespread glycogen accumulation as a key feature of AT cells and tissues, driven by dysregulated glucose metabolism and impaired mitochondrial respiration assessed with a multidimensional approach including metabolomics, flux analysis, histopathology, bioenergetic measurements, and electron tomography. These metabolic defects contribute to reduced cellular viability and premature senescence observed in AT patient-derived cells. Strikingly, inactivation of FNIP2, which controls mitochondrial respiration, partially rescues these defects in AT cellular models. We show that FNIP2 interacts with the SERCA2b calcium channel, and its inactivation enhances cytoplasmic calcium availability, stimulating mitochondrial respiration and increasing glucose consumption. This metabolic reprogramming prevents glycogen accumulation and improves survival in AT primary cells. Our findings provide novel insights into AT pathophysiology and indicate the FNIP2-SERCA2b axis as a novel potential target for mitigating the systemic effects of AT and improving outcomes in this complex disease.

Indexed as

Ataxia TelangiectasiaCarrier ProteinsMitochondriaSarcoplasmic Reticulum Calcium-Transporting ATPasesAnimalsAtaxia Telangiectasia Mutated ProteinsCalciumGlucoseGlycogenHumansMetabolic ReprogrammingAtaxia Telangiectasia Mutated ProteinsCalciumCarrier ProteinsGlucoseGlycogenSarcoplasmic Reticulum Calcium-Transporting ATPases

Identifiers

PMID41771847
PMCPMC13031930

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.